Mohammad Zhalechian, None;
Mark Van Oyen, National Eye Inst (F);
Mariel Lavieri, National Eye Inst (F);
Carlos De Moraes, Belite (C), Carl Zeiss (C), Galimedix (C), Heidelberg (R), Novartis (C), Perfuse Therapeutics (C), Reichert (C), Topcon (R);
Christopher Girkin, EyeSight Foundation of Alabama (F), Heidelberg Engineering, GmbH (F), National Eye Institute (F), Research to Prevent Blindness (F);
Massimo Fazio, EyeSight Foundation of Alabama (F), GmbH (F), Heidelberg Engineering (F), National Eye Institute (F), Research to Prevent Blindness (F);
Robert Weinreb, Aerie Pharmaceuticals (C), Allergan (C), Bausch&Lomb (F), Bausch&Lomb,Eyenovia (C), Carl Zeiss Meditec (F), Centervue (F), Eynovia (C), Heidelberg Engineering (F), Konan Medical (F), Meditec-Zeiss (P), Optovue (F), Toromedes (P);
Christopher Bowd, None;
Jeffrey Liebmann, Aerie (C), Alcon, Inc. (C), Allergen (C), Bausch & Lomb (F), Bausch & Lomb, Inc. (C), Carl Zeiss Meditec (F), Carl Zeiss Meditech, Inc. (C), Eyenova (E), Galimedex (C), Heidelberg Engineering (F), Heidelberg Engineering GmbH (C), National Eye Institute (F), Novartis (C), Optovue (F), Reichert (C), Reichert (F), Research to Prevent Blindness (F), Topcon (F);
Linda Zangwill, Carl Zeiss Meditec Inc. (F), Heidelberg Engineering (R), Heidelberg Engineering GmbH (F), Meditec-Zeiss (P), National Eye Institute (F), Optovue Inc. (F), Topcon Medical Systems Inc. (F);
Chris Andrews, National Eye Inst (F);
Joshua Stein, National Eye Inst (F)